TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06428968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 160 units nasal insulin spray
Description: Initially, a series of MRI scans, including high-resolution T1-weighted anatomical images, diffusion tensor imaging, resting-state functional MRI, and arterial spin labeling, will be conducted. Subsequently, 160 units of nasal insulin spray will be administered, followed by a second round of MRI scans after a 30-minute interval, encompassing high-resolution T1-weighted anatomical images, resting-state functional MRI, and arterial spin labeling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 160 units nasal insulin spray
Description: Initially, a series of MRI scans, including high-resolution T1-weighted anatomical images, diffusion tensor imaging, resting-state functional MRI, and arterial spin labeling, will be conducted. Subsequently, 160 units of nasal insulin spray will be administered, followed by a second round of MRI scans after a 30-minute interval, encompassing high-resolution T1-weighted anatomical images, resting-state functional MRI, and arterial spin labeling.
Study: NCT05069948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HeadOn
Description: HeadOn is a web application which takes the participant through a 5-stage CBT programme including: (i) understanding post-concussion symptoms; (ii) sleep after a concussion; (iii) lifestyle habits and exercise; (iv) managing negative thought patterns and (v) returning to baseline. The programme is delivered through a combination of weekly tasks (such as completing symptom diary, setting exercise goals and setting up a sleep time routine), audio/video media and reading material.
Study: NCT05183360

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 706321
Description: BI 706321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 706321
Description: BI 706321

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04760808

Intervention type: DIAGNOSTIC_TEST
Intervention: Baseline Clinical Examination
Description: Evaluations of Postural control; Subjective postural vertical; Subjective visual vertical; Verticality perception

Intervention type: DIAGNOSTIC_TEST
Intervention: Baseline Clinical Examination
Description: Evaluations of Postural control; Subjective postural vertical; Subjective visual vertical; Verticality perception

Intervention type: RADIATION
Intervention: Initial 3T MRI of the Brain and Spine
Description: Non-injected CSF flow MRI

Intervention type: RADIATION
Intervention: Initial 3T MRI of the Brain and Spine
Description: Non-injected CSF flow MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: 6-month Follow-up Clinical Examination
Description: Evaluations of Postural control; Subjective postural vertical; Subjective visual vertical; Verticality perception

Intervention type: RADIATION
Intervention: 6-month Follow-up 3T MRI of the Brain and Spine
Description: Non-injected CSF flow MRI
Study: NCT05121272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive task
Description: cognitive task

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive task
Description: cognitive task

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive task
Description: cognitive task

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive task
Description: cognitive task
Study: NCT05270434

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: time interval between ESWL and ERCP is 12h
Description: The patients received intravenous analgesia before the ESWL. After the last ESWL session, the patients are treated with following ERCP within 12h.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: time interval between ESWL and ERCP is greater than 12h
Description: The patients received intravenous analgesia before the ESWL. After the last ESWL session, the patients are treated with following ERCP ≥12 h.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid (Analgesics)
Description: Analgesics administrated include morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid. They will only be administrated as needed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid (Analgesics)
Description: Analgesics administrated include morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid. They will only be administrated as needed.
Study: NCT05910996

Intervention type: PROCEDURE
Intervention: Conversion from vv-ECMO to va-ECMO
Description: Conversion from vv-ECMO to va-ECMO
Study: NCT06094478

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HI-SPEED Protocol
Description: The HI-SPEED Protocol or Bundle consists of 7 components including 1) stroke screening scales, 2) imaging pathways, 3) telestroke operations, 4) a best practice alert, 5) stroke team communication tool, 6) door-to-needle (thrombolysis) treatment pathway, and 7) a standardized hand-off tool. This protocol will be implemented at each participating health system in clusters of 2 health systems.
Study: NCT05383196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: oral administration, once daily for 21 consecutive days, followed by 7 days without drug, to complete a cycle of 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onvansertib
Description: oral administration, once daily for 21 consecutive days, followed by 7 days without drug, to complete a cycle of 28 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: once a week into your vein (by intravenous infusion) over about 30 minutes. This will continue for 3 weeks of every cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: once a week into your vein (by intravenous infusion) over about 30 minutes. This will continue for 3 weeks of every cycle
Study: NCT05932238

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 400 and propylene glycol solution/drops - Preservative Free (PF)
Description: commercially available eye drops

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol 400 and propylene glycol solution/drops - Preserved
Description: commercially available eye drops
Study: NCT06573879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eccentric Exercise
Description: It was investigated whether volleyball athlete participants would develop muscle architecture, muscle strength and performance parameters differently from the control group by performing eccentric exercises in addition to their exercise routines.
Study: NCT05640193

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lifileucel (LN-144)
Description: A portion of the patient's tumor is resected and serves as the starting material for manufacturing lifileucel. After preparative NMA-LD, patients are infused with their autologous TIL (lifileucel), followed by a short course of high-dose IL-2.
Study: NCT04465344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantation of trifocal IOL, Isatis TF (device under investigation)
Description: Patients will be implanted with study IOL in both eyes

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of monofocal IOL, Isatis (control device)
Description: Patients will be implanted with Control IOL in both eyes
Study: NCT06653361

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Green laser
Description: Green Laser

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Green laser
Description: Green Laser
Study: NCT06655662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: β-globin restored autologous hematopoietic stem cells
Description: Eight transfusion-dependent β-thalassaemia subjects aged 6-35 years will be reinfused with β-globin restored autologous hematopoietic stem cells modified with LentiHBBT87Q
Study: NCT06655129

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intense pulsed light
Description: intense pulsed light (IPL) using the Medical Device Anthelia
Study: NCT06655116

Intervention type: BEHAVIORAL
Intervention: Diabetic Foot Education
Description: Patients in the intervention group will be interviewed and their diabetic foot knowledge will be evaluated. During the interview, the individual's knowledge about the definition of diabetic foot, risk factors, symptoms, treatment, complications, care and prevention will be evaluated.~In order to systematically plan, implement and evaluate the training to be used in the intervention, it is aimed to implement androgogical training based on the 'Interpersonal Relations Theory'. In this context, the stages in the theory will be followed as follows.
Study: NCT06588946

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone monoester (KME) supplement
Description: 15g of a KME supplement orally consumed 3x daily for 14 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: 50mL taste-match inert calorie-free placebo drink orally consumed 3x daily for 14 days
Study: NCT06590649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Household-level effects
Description: At 3 months, participants randomized to the PILI 'Āina intervention will receive a 6-month intervention centered around the use of a raised-bed home garden as the means of engaging household members to 1) increase their access to and intake of vegetables, 2) learn culturally relevant ways of preparing/cooking fresh vegetables through hands-on cooking lessons with local experts, and 3) build family cohesion through family bonding activities. Participants will be given all the equipment and materials (e.g., soil, seeds, instructions, setup of equipment) needed to grow their vegetables using their raised-bed home garden box throughout the entire study. They will receive seeds for the vegetables that can grow in a relatively short period (i.e., within 6 weeks). The household participants will be analyzed side by side with the index participants.
Study: NCT06603792

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EEG-neurofeedback
Description: Traditional neurofeedback uses one or two electrodes to modulate activity within a specific frequency band. Standardized Weighted Low Resolution Electromagnetic Tomography (swLORETA) analyzes the 3D distribution of intracortical brain electrical activity based on surface EEG recordings, enabling real-time brainwave imaging with a spatial resolution under one cubic centimeter. This divides the brain into over 12,000 voxels, offering localization similar to fMRI while maintaining EEG's faster temporal resolution. Source-localized NF can target specific, deeper brain regions, multiple Brodmann areas simultaneously, and provide feedback on connectivity between neural sources, enabling the training of specific neural networks. swLORETA metrics are compared to a normative database of neurotypical brains to produce z-scores for each area and metric. We will use the NeuroGuide normative database, FDA-approved and validated in peer-reviewed studies, widely used in clinical NF.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: EEG-neurofeedback
Description: Traditional neurofeedback uses one or two electrodes to modulate activity within a specific frequency band. Standardized Weighted Low Resolution Electromagnetic Tomography (swLORETA) analyzes the 3D distribution of intracortical brain electrical activity based on surface EEG recordings, enabling real-time brainwave imaging with a spatial resolution under one cubic centimeter. This divides the brain into over 12,000 voxels, offering localization similar to fMRI while maintaining EEG's faster temporal resolution. Source-localized NF can target specific, deeper brain regions, multiple Brodmann areas simultaneously, and provide feedback on connectivity between neural sources, enabling the training of specific neural networks. swLORETA metrics are compared to a normative database of neurotypical brains to produce z-scores for each area and metric. We will use the NeuroGuide normative database, FDA-approved and validated in peer-reviewed studies, widely used in clinical NF.
Study: NCT06590246

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Armored and GPC3-targeted autologous CAR T-cell
Description: Armored and GPC3-targeted autologous CAR T-cells, single infusion intravenously.
Study: NCT06595628

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lichtenstein Mesh-Based Hernioplasty
Description: This is a tension-free hernioplasty procedure that uses a synthetic mesh to reinforce the inguinal canal floor. The mesh is fixed to the inguinal ligament and internal oblique aponeurosis, creating a barrier to prevent hernia recurrence. It is considered the gold standard for inguinal hernia repair and is widely used for its effectiveness in reducing recurrence rates and postoperative complications.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Combined Modified Guarnieri-Desarda Tissue-Based Hernioplasty
Description: This technique combines elements of the Guarnieri and Desarda tissue-based repairs. It does not involve the use of synthetic mesh, relying instead on the patient's own tissues to reinforce the inguinal canal. The Guarnieri technique reshapes the internal ring to improve the inguinal canal's shutter mechanism, while the Desarda technique reinforces the posterior wall using the external oblique aponeurosis. This approach aims to preserve natural anatomy and minimize complications associated with mesh use.
Study: NCT06593899

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiotherapy
Description: Hypofractionated radiotherapy Preoperative hypofractionated 5x5 Gy radiotherapy (5 consecutive days) prescribed on planned target volume

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 cycles of AI
Description: Three courses of doxorubicin and ifosfamide (AI, doxorubicin 75 mg/sqm and ifosfamide 10 g/sqm with prophylactic mesna)
Study: NCT06604312

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sacroiliac Joint Manipulation
Description: Sacroiliac manipulation was performed using manual treatment method by lying patients on their sides. First, the patient was positioned firmly on the edge of the examination table, while the restricted sacroiliac joint remains on the upper side. Then, the physician's hand was positioned on the patient's hip, and the flexion was made on the lumbar spine with the movement from the hip to the upper thigh, and the impulse given by the HVLA technique was applied in the anteroinferior direction to the iliac crest and trochanter major.
Study: NCT06655688

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Acceptance and Commitment Therapy Based Intervention Program was applied to the intervention group in eight sessions online. Each session will last an average of 60-90 minutes. There will be two sessions for one group per week.
Study: NCT06591962

Intervention type: OTHER
Intervention: Questionnaire application for diabetes mellitus
Description: Scales will be applied to individuals diagnosed with diabetes mellitus

Intervention type: OTHER
Intervention: Questionnaire application for without diabetes mellitus
Description: Scales will be applied to individuals diagnosed without diabetes mellitus
Study: NCT06603766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV Magnesium Sulfate
Description: MgSO₄'s mechanism in PPHN includes activating cellular processes, modulating membrane excitability, and acting as a physiological calcium antagonist. It exerts sedative, muscle relaxant, and bronchodilatory properties, while concurrently inducing a state of alkalosis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhalational magnesium sulfate
Description: It gives us the same mechanism of action as IV MgSO4 with less side effects.
Study: NCT06590597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EDUCATIONAL INTERVENTION FOR MALARIA PREVENTION
Description: The intervention consisted of 4 modules administered in the same number of face-to-face sessions in which educational strategies such as classes, guided discussions, workshops and a booklet designed for the study were used.
Study: NCT06603454

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative CT
Description: Preoperative contrast enhanced CT
Study: NCT06588595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasugrel/Ticagrelor monotherapy or aspirin plus clopidogrel
Description: After at least 30 days of DAPT \[with aspirin 81-mg qd and a potent P2Y12 inhibitor (prasugrel 10 mg qd or ticagrelor 90-mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients with an ABCD-GENE 10 or more will continue prasugrel 10 mg qd/ticagrelor 90 mg BID and drop aspirin; and patients with an ABCD-GENE less than10 will switch from prasugrel/ticagrelor-based DAPT to aspirin 81 mg qd plus clopidogrel 75 mg qd.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin plus clopidogrel
Description: After at least 30 days of DAPT \[with aspirin 81 mg qd and a potent P2Y12 inhibitor (prasugrel 10 mg qd or ticagrelor 90 mg BID)\] in chronic coronary syndrome or after at least 90 days of DAPT in acute coronary syndromes; patients will switch from prasugrel/ticagrelor-based DAPT to aspirin 81 mg qd plus clopidogrel 75 mg qd, irrespective of ABCD-GENE score.
Study: NCT06588309

Intervention type: BEHAVIORAL
Intervention: Eye movement desensitization and reprocessing (EMDR)
Description: Integrated addiction and traumafocused treatment.

Intervention type: BEHAVIORAL
Intervention: Eye movement desensitization and reprocessing (EMDR)
Description: Integrated addiction and traumafocused treatment.

Intervention type: BEHAVIORAL
Intervention: CRA
Description: CRA is a comprehensive cognitive behavioural treatment that focuses on helping people discover and adopt a pleasurable, social and healthy lifestyle that is more rewarding than a lifestyle including substance use.

Intervention type: BEHAVIORAL
Intervention: CRA
Description: CRA is a comprehensive cognitive behavioural treatment that focuses on helping people discover and adopt a pleasurable, social and healthy lifestyle that is more rewarding than a lifestyle including substance use.
Study: NCT05104112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The M.E.R. program
Description: The M.E.R program is a therapeutic education intervention for mothers of children with ASD during a new pregnancy. This program, which is a pilot in France and in Europe, involves several dimensions, both pedagogical and behavioral (strategies for stimulating the baby, use of specific communication and interaction tools) and psychological (reduction of stress, anxiety, etc. in the mother).~It includes 8 individual interviews of 1h30 every 15 days. The first and the last one are for evaluation purposes, the 6 intermediate sessions constitute the accompaniment. The structure of the program and the sessions are based on what is recommended in therapeutic education. The sessions can take place on the hospital site or at home.
Study: NCT06604390

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: catechin extracts (health food)
Description: Type of intervention:~1. Purified gambir ≥ 90% (+)-Catechin~2. Dosage of 224 mg catechin capsule, once daily~3. Dosage of 224 mg placebo capsule, once daily~4. Cognitive function was assessed using MoCA-Ina and gene markers APP, MAPT, BDNF, IL-10, TGF-Beta and MDA Plasma.\&#34;

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: catechin extracts (health food)
Description: Type of intervention:~1. Purified gambir ≥ 90% (+)-Catechin~2. Dosage of 224 mg catechin capsule, once daily~3. Dosage of 224 mg placebo capsule, once daily~4. Cognitive function was assessed using MoCA-Ina and gene markers APP, MAPT, BDNF, IL-10, TGF-Beta and MDA Plasma.\&#34;
Study: NCT06398977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Dapagliflozin10MG, PO once daily
Study: NCT06604390

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: plasebo
Description: Dosage of 224 mg placebo per capsule, once daily. Cognitive function was assessed using the MoCA-Ina and biomarkers including APP, MAPT, BDNF, IL-10, TGF-Beta, and plasma MDA.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: plasebo
Description: Dosage of 224 mg placebo per capsule, once daily. Cognitive function was assessed using the MoCA-Ina and biomarkers including APP, MAPT, BDNF, IL-10, TGF-Beta, and plasma MDA.
Study: NCT05455879

Intervention type: OTHER
Intervention: Impact of antenatal corticosteroid therapy on surfactants use postnatal
Description: Intervention Description: Retrospective study on preterm infants to evaluate the impact of antenatal corticosteroid therapy on surfactants use postnatal
Study: NCT05714631

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: Transdermal placebo patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% Lidocaine Patch
Description: Transdermal patch
Study: NCT06475872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crecheck Tablet 2.5 mg
Description: 2 tablets orally once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crestor Tablet 5 mg
Description: 1 tablet orally once a day
Study: NCT06507995

Intervention type: DRUG
Group type: OTHER
Intervention: thoracic interlaminar epidural injection
Description: . Injections were administered under sedation and sterile conditions, with all patients positioned prone and monitored. A single physician performed all injections using an 18 gauge Tuohy needle, employing the loss of resistance technique and confirming the epidural space placement with 5 mL of nonionic contrast.

Intervention type: DRUG
Group type: OTHER
Intervention: thoracic interlaminar epidural injection
Description: . Injections were administered under sedation and sterile conditions, with all patients positioned prone and monitored. A single physician performed all injections using an 18 gauge Tuohy needle, employing the loss of resistance technique and confirming the epidural space placement with 5 mL of nonionic contrast.
Study: NCT06601231

Intervention type: DIAGNOSTIC_TEST
Intervention: GAAD score
Description: In order to calculate the GAAD score an in-vitro diagnostic is used. The Elecsys GAAD assay by Roche Diagnostics is used to assess the GAAD score using on blood samples collected from patients during regular outpatient clinic visits. The Elecsys GAAD test combines the results of the Elecsys PIVKA-II and Elecsys AFP assays with gender and age (the GAAD score is calculated with PIVKA-II, AFP, gender and age).